<DOC>
	<DOCNO>NCT00513253</DOCNO>
	<brief_summary>This study design estimate relative bioavailability alternative lapatinib oral formulation compare current tablet formulation .</brief_summary>
	<brief_title>A Phase I Study Test Alternate Oral Formulations v Current Tablet Formulation Lapatinib</brief_title>
	<detailed_description />
	<mesh_term>Lapatinib</mesh_term>
	<criteria>The subject healthy define per protocol . The subject male female . A female eligible enter participate study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female : Has document ( medical report verification ) hysterectomy double oophorectomy Is 6 week postsurgical bilateral oophorectomy without hysterectomy Is postmenopausal ( defined female older 45 year age 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level higher 40 mIU/ml ) Childbearing potential , negative serum pregnancy test Screening , agree one following : Complete abstinence sexual intercourse two week prior administration study drug throughout study , followup visit occur within 10 14 day completion last treatment . Vasectomized partner Intrauterine device ( IUD ) document failure rate le 1 % per year . Doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm ) . Hormonal contraceptive plus male condom . Age : 18 60 year inclusive . BMI within range 19 31.0 kg/m2 . Able swallow retain oral medication . The subject willing refrain use illicit drug adhere protocolstated restriction participate study . The subject able understand comply protocol requirement instruction likely complete study plan . A signed date write informed consent obtain subject subject 's legally acceptable representative prior screening . As result medical interview , physical examination screen investigation , Principal Investigator considers subject unfit study . The subject meet ECGrelated exclusion criterion list protocol serum magnesium potassium normal range screening . The subject history drug allergy , , opinion Principal Investigator , contraindicate participation . The subject know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , include limited Tarceva ( erlotinib ) Iressa ( gefitinib ) . The subject history sensitivity heparin heparininduced thrombocytopenia ( applicable heparin use pharmacokinetic sampling ) . The subject participate study new molecular entity trial previous 30 day . The subject donate blood excess 500 mL within 56 day prior dose intend donate month complete study . Use prescription nonprescription drug ( include vitamin herbal supplement ) within two week prior dose study , however , acetaminophen two gram per day acceptable . History alcohol/drug abuse dependence within 12 month study per protocol . The subject smoker smoke last four month . The subject test positive hepatitis C antibody , hepatitis B surface antigen , HIV antibody . The subject positive urine test drug abuse positive alcohol use prestudy screening . Consumption red wine , Seville oranges , grapefruit grapefruit juice 7 day prior first dose study medication collection final PK blood sample .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>lapatinib</keyword>
	<keyword>Healthy Adult Volunteer</keyword>
</DOC>